AI reports to help doctors judge bone damage risk in rheumatoid arthritis
Tests AI reports that help doctors choose treatment for adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: GenAI-Assisted Rheumatoid Arthritis Bone Erosion Risk Assessment and DMARD Selection
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Guang'anmen Hospital of China Academy of Chinese Medical SciencesBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Trial code
- NCT07914907
- Record updated
- 4 November 2026
- Original description
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and bone erosion. Accurate assessment of RA bone erosion risk (RABER) and appropriate disease-modifying antirheumatic drug (DMARD) selection are critical to preventing irreversible disability.Read full original descriptionShow less
Prospective Evaluation of Generative AI-Augmented Clinical Decision-Making for Rheumatoid Arthritis Bone Erosion Risk (RABER) Assessment and DMARD Selection in Routine Care
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and bone erosion. Accurate assessment of RA bone erosion risk (RABER) and appropriate disease-modifying antirheumatic drug (DMARD) selection are critical to preventing irreversible disability.
Recent advances in generative artificial intelligence (GenAI), particularly large language models (LLMs), enable integration of heterogeneous clinical data and may improve clinical decision-making. However, there is limited real-world evidence (RWE) evaluating whether GenAI can meaningfully augment physician decision-making in routine care.
This prospective, single-arm, nonrandomized interventional study evaluates the feasibility and impact of GenAI-assisted clinical decision support on physician assessment of rheumatoid arthritis bone erosion risk and disease-modifying antirheumatic drug selection in routine inpatient care. Treating physicians document their initial risk assessments and treatment decisions before reviewing patient-specific GenAI reports and subsequently record their assessments and decisions after reviewing the reports. The study evaluates changes in physician clinical decision-making within a learning health system framework. Final treatment decisions remain under the responsibility of the treating physicians. The study does not evaluate long-term patient clinical outcomes.
Inclusion: Newly diagnosed RA patients meeting American College of Rheumatology / European League Against Rheumatism 2010 classification criteria; Consecutive inpatients admitted during study period.
Exclusion: Patients subsequently determined not to have RA; Incomplete clinical data preventing risk or treatment assessment.